Inhibikase Therapeutics (IKT) Profit After Tax (2020 - 2024)
Historic Profit After Tax for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to -$12.1 million.
- Inhibikase Therapeutics' Profit After Tax fell 19039.62% to -$12.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$27.5 million, marking a year-over-year decrease of 4462.17%. This contributed to the annual value of -$27.5 million for FY2024, which is 4462.17% down from last year.
- Per Inhibikase Therapeutics' latest filing, its Profit After Tax stood at -$12.1 million for Q4 2024, which was down 19039.62% from -$5.8 million recorded in Q3 2024.
- Over the past 5 years, Inhibikase Therapeutics' Profit After Tax peaked at -$421869.0 during Q2 2020, and registered a low of -$12.1 million during Q4 2024.
- Over the past 5 years, Inhibikase Therapeutics' median Profit After Tax value was -$4.5 million (recorded in 2022), while the average stood at -$4.1 million.
- Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 56674.67% in 2021, then soared by 1512.54% in 2022.
- Inhibikase Therapeutics' Profit After Tax (Quarter) stood at -$1.2 million in 2020, then crashed by 317.36% to -$5.0 million in 2021, then increased by 15.13% to -$4.3 million in 2022, then rose by 2.36% to -$4.2 million in 2023, then crashed by 190.4% to -$12.1 million in 2024.
- Its last three reported values are -$12.1 million in Q4 2024, -$5.8 million for Q3 2024, and -$5.0 million during Q2 2024.